Lyon, France, January 25, 2022 /PRNewswire/ — genOway, a world leader in innovative genetically engineered research models, today announced that it has granted a non-exclusive CRISPR/Cas9 license to the world’s largest academic biomedical research funding institution. UK.
In December 2018, genOway has entered into an exclusive worldwide licensing agreement with Merck for the use of its fundamental CRISPR integration patents for preclinical applications in the field of rodents. genOway’s strategy is to provide a sub-license on this CRISPR technology to select partners and provide them with competitive advantages.
“This agreement, established with the main funder of the UK, combines research and business. It will help the pharmaceutical and biotechnology industries to access preclinical models and services based on CRISPR/Cas9 technology, developed by academic laboratories, while allowing them to promote their research to industrialists”, said Alexandre Fraichard, Founder and CEO of genOway.
“Thanks to our exclusive rights to CRISPR/Cas9 technology, our customers and partners have access to a full range of models, from those in which the genes of interest are inactivated, to “humanized” models in which mouse genes are replaced by their human counterparts, to models mimicking human disorders such as neurodegenerative diseases or rare diseases”, Explain Kader Thiam, vice president of transgenic technologies at genOway.
In the coming months, genOway will be rolling out this approach with other academic research funders, preclinical service providers (such as contract research organizations, CROs) and catalog model providers to enable them to ‘include all CRISPR/Cas9-based models in their offerings and provide their customers with the necessary freedom of action.
“We are the only company to hold licenses under all three core CRISPR patent portfolios available today. This allows us to differentiate ourselves from our competitors while protecting our customers against the risks of infringement, and to offer competitive advantages to selected sub-licensees”, adds Alexandre Fraichard.
A world leader in the field of genetic engineering since 1999, genOway designs and develops preclinical cell or rodent research models.
The company has developed more than 2,500 research models for the pharmaceutical industry and the most prestigious academic research laboratories, contributing to the development of numerous treatments and therapeutic drugs.
genOway is listed on the Euronext Paris stock exchange.
ISIN Code: FR0004053510 – ALGEN
For more information: [email protected]
Logo – https://mma.prnewswire.com/media/1732533/genOway_Logo.jpg
View original content for multimedia download: https://www.prnewswire.com/news-releases/genoway-grants-the-leading-uk-academic-research-funder-a-non-exclusive-license-for-crisprcas9 -technology-301466655.html